Helus Pharma Adds Robert Langer and Stephen Brannan to Scientific Advisory Board

Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced the appointments of Dr. Robert Langer and Dr. Stephen Brannan to its Scientific Advisory Board, bolstering its expertise in biotechnology, drug delivery, and central nervous system clinical development. The company is advancing its pipeline of novel serotonergic agonists (NSAs) targeting major depressive disorder and generalized anxiety disorder, addressing unmet needs in mental health.

Dr. Robert Langer, a renowned figure in biotechnology and drug delivery, brings decades of experience in developing innovative therapies. Dr. Stephen Brannan adds expertise in CNS clinical development, having contributed to multiple successful psychiatric drug programs. Their appointments align with Helus Pharma's disciplined, evidence-based approach to drug development.

Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary NSAs designed to activate serotonin pathways and promote neuroplasticity. The company's lead candidate, HLP003, is in Phase 3 clinical development for adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.

The addition of Dr. Langer and Dr. Brannan is expected to accelerate the development of these programs. For more details, see the full press release here. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. More information is available at www.helus.com.